Medtronic has launched new research into AI's potential to identify patients with severe aortic stenosis and other worrying symptoms. The company hopes to overcome longstanding health disparities and reach individuals who may otherwise go untreated.
TAVR patients in this study were treated with early-generation devices that have since been updated, but researchers still believe their data are relevant to today's care teams.
Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
The new data, presented during AHA Scientific Sessions 2024, suggest LAAC with Boston Scientific's Watchman FLX could be a safe, effective alternative to OAC for limiting post-ablation strokes.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
The popular DOAC was linked to more bleeding events than warfarin, but fewer reports of intracardiac thrombi and other adverse outcomes. Researchers presented their findings at the AHA's Scientific Sessions 2024 conference in Chicago.
![Left atrial appendage occlusion (LAAO) with the Watchman FLX device from Boston Scientific is associated with positive outcomes and limited adverse events after one year, according to new findings published in Circulation: Cardiovascular Interventions.[1] Many prior Watchman FLX studies, including PINNACLE FLX, had focused on the device’s performance in a controlled setting. The study’s authors hoped to gain a better understanding of its real-world impact by reviewing registry data from more than 97,000 U.S](/sites/default/files/styles/top_stories/public/2024-08/screenshot_2024-08-12_at_11.35.13_am.png.webp?itok=5FeQeMFj)
